- Contrast medium of the impurity F synthetic method and its impurity G contrast medium, impurity H and impurity M application in the synthesis of
-
The invention relates to a synthesis method of contrast medium impurities, in particular to a contrast medium impurity F synthetic method and its in the contrast medium impurity G, impurity H and M application in the synthesis of the impurity, which belongs to the field of medical technology. The method is to 5 - nitro - 1, 3 - benzene dicarboxylic acid dimethyl ester (formula 2 compound) and 2, 3 - dihydroxy propylamine as raw materials of formula 3 compound, type 3 compound with hydrogen reduction reaction [...] 4 compound, of formula 4 with a compound obtained by reaction of the impurity F [...] contrast medium. The invention relates to 5 - nitro - 1, 3 - benzene dicarboxylic acid dimethyl ester (formula 2 compound) as the starting material, the synthesis of 5 - amino - N, double-N' - (2, 3 - dihydroxy-propyl) - diiodo - 1, 3 - benzene dicarboxylic amide (formula 1 compounds) and then to of formula 1 as the starting material for the synthesis of impurity G, impurity H and impurity M, for the contrast medium quality control to provide acceptable impurity reference substance.
- -
-
-
- 9 - Azabicyclo [3.3.1] nonane coupling [...] compound and its preparation method and use thereof (by machine translation)
-
The invention discloses a 9 - azabicyclo [3.3.1] nonane coupling [...] compound, its preparation method comprises the following steps: in the organic solvent, the 9 - nitrogen (6' - amino) oneself amidogen - 9 - 9 - azabicyclo [3.3.1] nonane - 3 α - alkyl amino formic acid benzene and chloro acetyl three iodo aniline derivatives in accordance with the 1: 1.0 - 1.5 molar ratio, for the catalysis of cesium hydroxide at room temperature reaction in the 20 - 30 the H, obtained as the product of the 9 - azabicyclo [3.3.1] nonane coupling [...] compound. The invention also discloses the use thereof: a contrast agent for early diagnosis of breast cancer. (by machine translation)
- -
-
Paragraph 0058; 0060; 0063
(2018/11/22)
-
- IODINATION PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED-2,4,6-TRIIODO AROMATIC AMINES COMPOUNDS
-
The invention discloses a improved process for the preparation of 3,5-disubstituted- 2,4,6-triiodo aromatic amines of formula (II), wherein R1 and R2 are defined as herein. The compounds of formula (II) are the key intermediates for the synthesis of a series of non-ionic contrast agents such as Iopamidol, Iohexol and Iodixanol. The process comprises reacting chlorine-free iodinating reagents with 3,5-disubstituted-2,4,6-triiodo aromatic amines to obtain 3,5-disubstituted-2,4,6-triiodo aromatic amines of formula (II), wherein the molar yield of the iodination reaction can reach to 89%.
- -
-
-
- CONTINUOUS PROCESS OF PREPARING INTERMEDIATE FOR NON-IONIC X-RAY CONTRAST AGENTS
-
This invention relates to an improved method for the synthesis of 5-amino-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound B), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a continuous process of the iodination reaction followed by the purification of Compound B.
- -
-
Page/Page column 3
(2011/02/18)
-
- Decolorizing 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide, a contrast media intermediate
-
This invention relates to an improved method for the synthesis of 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound B), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a process for decolorizing said intermediate.
- -
-
Page/Page column 5
(2011/02/26)
-
- CRYSTALLIZATION OF AN INTERMEDIATE FOR SYNTHESIZING NON-IONIC X-RAY CONTRAST AGENTS
-
This invention relates generally to the crystallization process of 5-amino-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide (“Compound B”), an iodinated intermediate in the preparation of non-ionic X-ray contrast agents. The instant process utilizes a nanofiltration system to pass through low molecular weight salt, thereby reducing the solubility of Compound B in the retentate. This process increases supersaturation of the mother liquor and improves crystal growth in the crystallization following the initial one. The process of the present invention is useful in increasing the overall crystallization yield of Compound B in an industrial manufacturing process.
- -
-
Page/Page column 3
(2011/02/18)
-
- Improvements in crystallization of 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6,-triiodo-isophthalamide, an intermediate for synthesizing non-ionic X-ray contrast agents
-
This invention relates to the crystallization process of 5-amino-N, N'- bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide ("Compound B"), an iodinated intermediate in the preparation of non-ionic X-ray contrast agents. The instant process utilizes a nanofiltration system to pass through low molecular weight salt, thereby reducing the solubility of Compound B in the retentate. This process increases supersaturation of the mother liquor and improves crystal growth in the crystallization following the initial one. The process of the present invention is useful in increasing the overall crystallization yield of Compound B in an industrial manufacturing process.
- -
-
Page/Page column 4-5
(2011/02/26)
-
- Yellow polymorph of 5-amino-2,4,6-triiodo-n,n′-bis(2-3-dihydroxypropy)-isophthalamide
-
The yellow polymorph of 5-amino-2,4,6-triiodo-N,N′-bis(2,3-dihydroxypropyl)-isophthalamide is described.
- -
-
-
- Urea-linked, iodinated bis phenyl compounds for X-ray contrast media
-
The invention provides iodinated bis phenyl compounds, useful as X-ray contrast agents, of formula I STR1 (wherein each C6 R5 moeity may be the same or different; each R denotes a hydrogen or iodine atom or a group M, two or three non-adjacent R groups on each C6 R5 moiety denoting iodine atoms and one, two or three R groups on each C6 R5 moiety denoting M groups; X denotes a group providing a 1, 2 or 3 atom chain linking the two C6 R5 groups, preferably where X is or contains in the bridging chain a carbonyloxy group each C6 R5 group being a triodophenyl group or a group in which each R is other than hydrogen; and each M is independently a non-ionic hydrophilic moiety, M preferably being a non-ionic hydrophilic moiety comprising a monohydroxy- or polyhydroxy-alkyl group) and isomers, especially stereoisomers and rotamers, thereof.
- -
-
-
- Heterocyclic Nonionic X-ray Contrast Agents. 3. The Synthesis of 5--2,4,6-triiodo-1,3-benzenedicarboxamide Derivatives
-
The syntheses of 2,4,6-triiodo-1,3-benzenedicarboxamide analogs, 12c, 12e, and 17c, of interest as X-ray diagnostic agents and in which the 5 position is linked to the N atom of a 4-(hydroxymethyl)-oxazolidin-2-one moiety, are described.The heterocycle was built from suitably protected 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid derivatives by a three-step procedure consisting of (1) phosgene treatment to obtain the corresponding isocyanates, (2) phenylmercuric chloride-catalyzed addition of glycidol (10) resulting in glycidil carbamates, and (3) pyridine-catalyzed intramolecular N-alkylation, followed by deprotection, to obtain the oxazolidin-2-ones.The intramolecular N-alkylation reaction was highly regioselective and was not appreciably accompanied by O-alkylation products under the experimental conditions employed.The two carboxamide nitrogen atoms in the intermediates and end products carry either 2,3-dihydroxypropyl or 1,3-dihydroxypropyl residues.These highly congested benzenoid compounds exhibited interesting NMR spectral features due to atropisomerism arising from hindrance to free rotation about the three single bonds that link the aromatic moiety to the N-containing functionalities.
- Pillai, K. M. R.,Diamantidis, G.,Duncan, L.,Ranganathan, R. S.
-
p. 1344 - 1350
(2007/10/02)
-
- Process for the preparation of 2,4,6-triiodo-5-amino-N-alkylisophthalamic acid and 2,4,6-triiodo-5-amino-isophthalamide compounds
-
An improved process for preparing a compound selected from among 2,4,6-triiodo-5-amino-N-alkylisophthalamic acid, salts thereof, esters thereof, 2,4,6-triiodo-5-amino-isophthalamide, 2,4,6-triiodo-5-amino-N-hydroxyalkyl-isophthalamide and 2,4,6-triiodo-5-amino-N,N'-bishydroxyalkyl-isophthalamide. A substrate selected from among 5-amino-N-alkylisophthalamic acid, salts thereof, esters thereof 5-amino-isophthalamide, 5-amino-N-hydroxyalkyl-isophthalamide and 5-amino-N,N'-bishydroxyalkylisophthalamide is reacted with an iodine halide in an aqueous reaction medium. In accordance with the improvement, the substrate and a source of the iodine halide are added to the reaction medium at such relative rates that, at any instant substantially throughout the addition cycle, the substrate is present in stoichoimetric excess over the iodine halide, but the difference between the cumulative amount of the substrate that has been added to the medium at such instant, expressed as a proportion of the total ultimate charge of the substrate, and the cumulative amount of the source of iodine halide that has been added to the medium at such instant, expressed as a proportion of the total ultimate charge of the source of iodine halide, does not exceed 10%. When the substrate is 5-amino-isophthalamide, 5-amino-N-hydroxyalkyl-isophthalamide or 5-amino-N,N'-bishydroxyalkyl-isophthalamide, the cumulative amount of the iodine halide may be in stoichiometric excess of not more than about 10% of the substrate computed on the same basis. Further improvements, respectively comprising incorporation of an alkaline buffer composition and operation at relative high dilution, are also disclosed.
- -
-
-
- Chemical compounds
-
Compounds of the formula: STR1 wherein R represents the group --CH2 CH2 OH or --CH2 CHOHCH2 OH, particularly in racemic or optically active form, are employed as active ingredients in X-ray contrast agents for intracerebral, but particularly for vascular use. The compounds are prepared by reacting 5-(N-acetamido)-2,4,6-triiodo-N,N'-bis-(2,3-dihydroxypropyl)isophthalamide or an O-acetyl derivative thereof with an appropriate hydroxyalkylating agent and subsequently, if necessary, hydrolysing any unwanted O-acetyl groups.
- -
-
-
- N,N'-Bis-(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-keto-L-gulonamido)isophthalamide and radiological compositions containing same
-
Novel X-ray contrast agents, i.e., N,N'-bis-(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-keto-L-gulonamido)isophthalamide, and intermediates.
- -
-
-
